Molecular Partners Ag (MOLN) Net Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Net Margin of 97.82% for Q1 2026, up 610.0% year-over-year from 13.78% in Q1 2025, and down 100.07% quarter-over-quarter from 143942.29% in Q4 2025.
Molecular Partners Ag (MOLN) Net Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Net Margin for 7 consecutive years, with 97.82% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 610.0% year-over-year to 97.82%; the TTM figure through Mar 2026 stood at 2203566.36% (up 220357428.0% YoY), while the FY2025 annual figure was 138209982.79%, down 269379001721.0% from the prior year.
- Net Margin retreated to 97.82% in Q1 2026 per MOLN's latest filing, from 143942.29% in the prior quarter.
- Across five years, Net Margin topped out at 1097627.06% in Q4 2024 and bottomed at 972404.9% in Q2 2024.
- Historically, Net Margin has averaged 15480.27% across 5 years, with a median of 97.82% in 2026.
- On a YoY basis, Net Margin climbed as much as 109853623 bps in 2024 and fell as far as 96855261 bps in 2024.
- Molecular Partners Ag's Net Margin stood at 82.13% in 2022, then plunged by 1207 bps to 909.17% in 2023, then surged by 120828 bps to 1097627.06% in 2024, then plunged by 87 bps to 143942.29% in 2025, then tumbled by 100 bps to 97.82% in 2026.
- Business Quant data shows MOLN's Net Margin at 97.82% in Q1 2026, 143942.29% in Q4 2025, and 98.31% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.82% |
| Dec 31, 2025 | 143,942.29% |
| Sep 30, 2025 | -98.31% |
| Jun 30, 2025 | -117.82% |
| Mar 31, 2025 | -103.92% |
| Dec 31, 2024 | 1,097,627.06% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | -972,404.90% |
| Mar 31, 2024 | -413.83% |
| Dec 31, 2023 | -909.17% |
| Sep 30, 2023 | -450.40% |
| Jun 30, 2023 | -3,852.29% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.13% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -38.46% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.80% |
| Sep 30, 2021 | -348.55% |
| Jun 30, 2021 | 3.43% |